Schering-Plough will provide additional data during this quarter.

FDA has asked Schering-Plough for supplemental data from an existing database and proposed labeling for Saphris sublingual tablets. The labeling details cover both indications in the NDA: acute treatment of schizophrenia in adults and in acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

No additional clinical trials have been requested. Schering-Plough anticipates providing the requested information to the agency this first quarter.

Schering-Plough acquired asenapine in November 2007 through its $14 billion takeover of Organon BioSciences, which developed the antipsychotic agent. The NDA for asenapine includes data from a clinical trial program involving more than 3,000 patients in schizophrenia and bipolar mania trials.


Previous articleJ.P. Morgan Healthcare Conference—Tuesday, January 13 Update
Next articleVistaGen and Capsant to Develop Stem Cell Technology for Drug R&D